Executive Summary
Azurity Pharmaceuticals failed to convince the PTAB that EXELIXIS's drug formulation patent was unpatentable, resulting in a denial of institution for IPR2025-00210. The Board rejected anticipation arguments based on prior art family relationships and dismissed obviousness claims regarding impurity control.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Azurity Pharmaceuticals, Inc. vs EXELIXIS, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Senko Advanced Components, Inc. et al.vsUS Conec Ltd.
Petitioner Senko Advanced Components challenges U.S. Conec's patent (11385415) in a Petition, asserting that claims are unpatentable under both anticipation (§102) and obviousness (§103). The challenge relies on multiple combinations of prior art references related to optical connectors and adapters.
Abbott Diabetes Care Inc. et al.vsDexCom, Inc.
Abbott Diabetes Care Inc. successfully secured institutional status in an IPR against DexCom, Inc., regarding continuous glucose monitoring systems. The Board found sufficient evidence that prior art references anticipate or render obvious key claims related to transcutaneous sensors and drift profiles.
Visa, Inc.vsCortex MCP, Inc.
Visa, Inc. successfully defended the Board's Final Written Decision in a Director Review proceeding against Cortex MCP, Inc., affirming that the challenged claims were unpatentable based on prior art Oborne.
CISCO SYSTEMS, INC.vsUMBRA TECHNOLOGIES LTD.
Cisco Systems successfully petitioned to challenge Umbra Technologies' patent (11146632) in the PTAB, arguing that the claims are unpatentable over prior art. The petition asserts that the patented technology is anticipated or obvious by the Agarwala reference and related knowledge of a POSITA.
Guardant Health, Inc.vsCold Spring Harbor Laboratory
The USPTO Board denied the institution of an Inter Partes Review (IPR) petition. The denial was based on a review of the merits, finding that the petitioner could not demonstrate a reasonable likelihood of prevailing.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.